Drug intelligence / Profile preview

dermatophagoides allergenic extract

Development stage
Unknown
Lead developer
Lofarma
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Percutaneous, Subcutaneous, Sublingual, Intradermal
01

Overview

Dermatophagoides allergenic extract is a biological product derived from house dust mites of the genus *Dermatophagoides*, primarily *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. Developed by LOFARMA S.p.A., it is utilized for both the diagnosis and treatment of respiratory allergies, such as allergic rhinitis and allergic asthma. The extract functions by interacting with allergen-specific IgE antibodies on the surface of mast cells and basophils; in diagnostic skin prick testing, this interaction triggers the release of inflammatory mediators like histamine. In the context of allergen-specific immunotherapy (AIT), the extract is administered to modulate the patient's immune response, inducing long-term desensitization and immune tolerance. The product has been evaluated in Phase 2 in-vivo biological standardization studies to define its activity in histamine equivalent prick (HEP) units.

Other names
House dust mite allergenic extractDermatophagoides pteronyssinus and Dermatophagoides farinae extractHDM allergenic extractHouse dust mite extract
02

Targets

House dust mite allergen-specific T-cell receptor (HDM-specific TCR)pMHC-II (Peptide-major histocompatibility complex class II complex)BCR (Immunoglobulin G B Cell Receptor)FcγRIIb (Low affinity immunoglobulin gamma Fc receptor IIb)

Beyond the preview

Go deeper on dermatophagoides allergenic extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dermatophagoides allergenic extract.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call